Neurocrine Biosciences (NASDAQ:NBIX) Director George Morrow Sells 300 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 300 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $149.00, for a total transaction of $44,700.00. Following the completion of the transaction, the director directly owned 10,386 shares of the company’s stock, valued at $1,547,514. The trade was a 2.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Up 13.4%

NBIX stock opened at $164.85 on Wednesday. The stock has a market capitalization of $16.76 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $186.12. The firm has a 50 day moving average of $146.72 and a 200 day moving average of $147.60.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. Neurocrine Biosciences’s revenue for the quarter was up 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.04 EPS. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Sunday, August 9th. UBS Group reduced their target price on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. TD Cowen lifted their price target on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Truist Financial boosted their price target on Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald increased their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $201.55.

Institutional Trading of Neurocrine Biosciences

Several large investors have recently made changes to their positions in NBIX. Bank of America Corp DE boosted its holdings in Neurocrine Biosciences by 10.6% during the first quarter. Bank of America Corp DE now owns 583,827 shares of the company’s stock worth $76,913,000 after buying an additional 55,723 shares in the last quarter. ABN AMRO Bank N.V. purchased a new position in Neurocrine Biosciences in the second quarter valued at $2,510,000. Focus Partners Advisor Solutions LLC purchased a new position in Neurocrine Biosciences in the second quarter valued at $1,927,000. Engineers Gate Manager LP increased its holdings in Neurocrine Biosciences by 64.0% in the second quarter. Engineers Gate Manager LP now owns 18,361 shares of the company’s stock valued at $3,094,000 after buying an additional 7,163 shares in the last quarter. Finally, SEB Asset Management AB acquired a new position in shares of Neurocrine Biosciences in the first quarter worth about $10,483,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, exceeding estimates, while EPS of $3.29 also topped consensus. Product sales surpassed $1 billion for the first time. Neurocrine raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, citing demand across its portfolio. Third-quarter results
• Positive Sentiment: Several analysts raised price targets after the results: Canaccord to $220, Piper Sandler to $215, RBC to $190, and Morgan Stanley to $185. Ratings ranged from buy/outperform to equal weight, so the target increases were broadly supportive but not uniformly bullish.
• Positive Sentiment: The company said it has begun a Phase 2 Alzheimer’s study and plans to present its neuroscience work and pipeline at the NEI Fall Congress. These updates add to investor focus on longer-term development opportunities, though the supplied reports provide limited study details. Alzheimer’s study and education update
• Negative Sentiment: Director George J. Morrow reported sales totaling 15,000 shares across transactions on November 2–3, in addition to a 300-share sale on October 30. The filings say the transactions were made under a pre-arranged Rule 10b5-1 plan, which may temper concern, and he retained 10,386 shares.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.